American Diabetes Association 83rd Scientific Sessions (ADA 2023)

Weight loss with high-dose oral semaglutide in obese nondiabetics

Elvira Manzano, 20230906000000

A higher dose of oral semaglutide than the currently approved 14 mg/day dose may be the next option for overweight or obese patients wanting to lose pounds.

Kids with T2D face dreadful complications

Elvira Manzano, 20230801000000

Children with type 2 diabetes (T2D) face a strikingly high complication rate as they become young adults, with an 80 percent incidence of at least one vascular complication, as shown in the TODAY* study.

Type 2 diabetes: Semaglutide pill works just as well as injectable

Jairia Dela Cruz, 20230722140000

Treatment with either oral or subcutaneous semaglutide yields favourable outcomes for patients with type 2 diabetes (T2D), according to real-world data.

Semaglutide, insulin degludec sustain glycaemic control in patients with T2D

Elaine Soliven, 20230722000000

Treatment with once-weekly subcutaneous semaglutide and once-daily insulin degludec sustained an HbA_1c level of ≤7.5 percent in individuals with adequately controlled type 2 diabetes (T2D) who were on multiple daily injections of insulin (MDI) regimen, according to the TRANSITION-T2D study presented at ADA 2023.

Metabolic surgery bests medical/lifestyle management for people with diabetes in the long run

Jairia Dela Cruz, 20230721140000

Individuals with type 2 diabetes (T2D) may fare better with metabolic bariatric surgery, which confers more favourable long-term outcomes as compared with intensive medical and lifestyle management, based on the 7- and 12-year data from the ARMMS-T2D* trial.

Tirzepatide induces weight loss in overweight/obese patients with T2D

Elaine Soliven, 20230720000000

Treatment with once-weekly tirzepatide, a GIP* and GLP-1** receptor agonist, led to a substantial weight reduction among overweight or obese adults with type 2 diabetes (T2D), according to the phase III SURMOUNT-2 trial presented at ADA 2023.

Metformin potentially cardioprotective for type 1 diabetes

Metformin discontinuation ups cardio-renal events in CKD patients with diabetes

Stephen Padilla, 20230718120000

Putting an end to the use of metformin may lead to a higher risk of cardio-renal events in patients with diabetes and advanced chronic kidney disease (CKD), regardless of their cardiovascular disease (CVD) status, suggests a study presented at ADA 2023.

SGLT2 inhibitors tied to kidney benefits, reduced MACE risk

Stephen Padilla, 20230717120000

Treatment with sodium-glucose lowering co-transporter 2 inhibitors (SGLT2i) helps arrest the decline in estimated glomerular filtration rate (eGFR) and is associated with a lower risk of adverse kidney events among adults with diabetes, irrespective of baseline albuminuria status, as shown in a study presented at the recent ADA 2023.

Meal replacement trumps food-based diet for improving CV risk factors in obese adults

Audrey Abella, 20230717100000

In the secondary and exploratory analyses of the OPTIWIN trial, meal replacement (MR) outdid a food-based (FB) regimen in improving cardiometabolic risk in adults with obesity.

‘Triple-G’ obesity drug also targets NAFLD in phase II trial

Audrey Abella, 20230711122956

In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).